Enobosarm demonstrated a statistically significant benefit in preserving lean mass in patients with overweight or obesity ...
(Reuters) -Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed ...
Although RMD has re-rated from its share price low of around $21.50 in October 2023, it has only just surpassed its all-time ...
A recent study from Karolinska Institutet suggests that a type of diabetes medication called GLP-1 agonists could reduce the ...
Several years ago, a little-known drug named Ozempic — previously used only to treat diabetes — emerged as a promising new ...
The widespread acceptance of the so-called GLP-1 drugs, Zepbound by Eli Lilly and Wegovy by Novo Nordisk, for weight loss has created a game-changing dynamic for the overall health of the 72% of ...
Robert F. Kennedy Jr., President Trump’s nominee for Health and Human Services secretary, sat through his second Senate ...
Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...
The Trump administration’s Centers for Medicare and Medicaid Services (CMS) has signaled that it will be revamping the ...
If you’re in a calorie deficit – either from dieting or while taking a weight loss drug – these exercises help direct your ...
The FDA issued a warning letter to ProRx, a compounding facility in Exton, Penn., after an inspection raised serious concerns regarding the safety and compliance of its drug products. The facility, ...
AI in drug development is a vague term that might mean many things, and today, Owkin is announcing it has enrolled the first patient in a phase 1 study of OKN4395, its “AI-optimized” candidate for ...